FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 322:303-308 February 1, 1990 Number 5 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

The use of the dried-blood immunoreactive-trypsin assay for the detection of cystic fibrosis in newborns has been questioned on the grounds that it may fail to identify patients with enough pancreatic function to have normal fat absorption. To investigate this possibility, we assessed pancreatic function in 78 patients identified in a neonatal screening program as having cystic fibrosis. The diagnosis of cystic fibrosis was confirmed by abnormal results on a sweat chloride test. The results of measurements of fecal fat excretion, pancreatic-stimulation tests, and estimations of the serum level of pancreatic isoamylase indicated that 29 of the 78 children (37 percent) had substantial preservation of pancreatic function. These children (median age, four years) had growth that was close to normal and comparable to growth in children with severe pancreatic insufficiency who received oral enzyme therapy. Pancreatic insufficiency subsequently developed in 6 of the 29 patients, at 3 to 36 months of age. We conclude that the serum immunoreactive-trypsin assay used in neonatal screening programs identifies patients with cystic fibrosis who have sufficient pancreatic function to have normal fat absorption and that a substantial proportion of infants identified as having cystic fibrosis are in this category.

Source Information

Department of Gastroenterology, Royal Alexandra Hospital for Children, Camperdown, Sydney, Australia.

This article has been cited by other articles:

• Schneider, A., Funk, B., Caspary, W., Stein, J. (2005). Monoclonal versus Polyclonal ELISA for Assessment of Fecal Elastase Concentration: Pitfalls of a New Assay. Clin. Chem. 51: 1052-1054 [Full Text]  
• Chen, A. H, Innis, S. M, Davidson, A G. F, James, S J. (2005). Phosphatidylcholine and lysophosphatidylcholine excretion is increased in children with cystic fibrosis and is associated with plasma homocysteine, S-adenosylhomocysteine, and S-adenosylmethionine. Am. J. Clin. Nutr. 81: 686-691 [Abstract] [Full Text]  
• Durie, P. R., Kent, G., Phillips, M. J., Ackerley, C. A. (2004). Characteristic Multiorgan Pathology of Cystic Fibrosis in a Long-Living Cystic Fibrosis Transmembrane Regulator Knockout Murine Model. Am. J. Pathol. 164: 1481-1493 [Abstract] [Full Text]  
• Carrere, J, Guy-Crotte, O, Gaia, E, Figarella, C (1999). Immunoreactive pancreatic Reg protein in sera from cystic fibrosis patients with and without pancreatic insufficiency. Gut 44: 545-551 [Abstract] [Full Text]  
• Waters, D. L, Wilcken, B., Irwig, L., Van Asperen, P., Mellis, C., Simpson, J. M, Brown, J., Gaskin, K. J (1999). Clinical outcomes of newborn screening for cystic fibrosis. Arch. Dis. Child. Fetal Neonatal Ed. 80: 1F-7 [Abstract] [Full Text]  
• Farrell, P. M., Kosorok, M. R., Laxova, A., Shen, G., Koscik, R. E., Bruns, W. T., Splaingard, M., Mischler, E. H., The Wisconsin Cystic Fibrosis Neonatal Screening S, (1997). Nutritional Benefits of Neonatal Screening for Cystic Fibrosis. NEJM 337: 963-969 [Abstract] [Full Text]